Pharmaceutical firm Eton Q3 product sales up

Eton Pharmaceuticals

06/11/2025 22:17

Overview

Eton Q3 2025 product sales rise 129% yr/yr to $22.5 mln

Company reports Q3 non-GAAP EPS of $0.04, despite GAAP EPS loss of $0.07

ET-600 NDA accepted by FDA, PDUFA date set for Feb 25, 2026

Outlook

Company expects to launch ET-600 in Q1 2026

Result Drivers

PRODUCT SALES GROWTH - Eton's Q3 2025 product sales increased by 129% yr/yr, driven by ALKINDI SPRINKLE, Carglumic Acid, INCRELEX, and GALZIN

INCRELEX RELAUNCH - INCRELEX relaunch exceeded expectations, becoming the largest revenue contributor in Q3 2025

GALZIN ADOPTION - GALZIN relaunch saw strong adoption, with accelerated uptake in Q3 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.07
Q3 Net Income
-$1.93 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $29.00, about 33.6% above its November 5 closing price of $19.25

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nGNXwFMHH

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)